HYPOPhosphatemia in the Intensive Care: A One-day Point Prevalence Survey

Critically Ill Clinical Trial

— HYPO-P-ICU  

Official title:

Hypophosphatemia in the ICU - A One-day Point Prevalence Survey

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04201899
• Other study ID #: CER2019-02343
• Secondary ID: 2019-021-406
• Status: Completed
• Start date: March 9, 2020
• Est. completion date: July 31, 2020

Study information

• Verified date: January 2021
• Source: Centre Hospitalier Universitaire Vaudois
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The point prevalence survey aims at defining the until now unknown real prevalence of hypophosphatemia (defined as blood phosphate value < 0.8 mmol/l) in international critical care settings

Description:

The survey will be conducted on one single day in each centre (D-day), within a week defined by the project coordinator (International PI). On D-Day, the local investigators will be asked 1. to complete questions aiming at describing their ICU (number of beds, number of patients present on D-Day, type medical/surgical/other, local phosphate reference value, presence of an hypophosphatemia treatment protocol in the ICU and route of phosphate delivery in case of hypophosphatemia) 2. to indicate how many patients had a blood phosphate <0.08 mmol/l, for each patient with hypophosphatemia, to record the exact lowest value on D-Day, and to record age, number of days in ICU on D-Day, presence (or not) of artificial nutrition and continuous renal replacement therapy, if any phosphate administration is ongoing Data will be recorded in and electronic Case Report Form (e-CRF) in REDCap, and analysed with descriptive statistics No outcome data will be recorded (pure point-prevalence) There is no intervention

Recruitment information / eligibility

• Status: Completed
• Enrollment: 890
• Est. completion date: July 31, 2020
• Est. primary completion date: July 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria: blood phosphate value < 0.8 mmol - Exclusion Criteria: Blood phosphate value >0.8 mmol/l -

Related Conditions & MeSH terms

• Critical Illness
• Critically Ill
• Hypophosphatemia

Intervention

Dietary Supplement:
• No intervention - pure observation
Phosphate administration (yes or no)

Locations

Country	Name	City	State
Estonia	Tartu University Hospital	Tartu
France	Hôpital Pasteur 2	Nice
Switzerland	Lausanne University Hospital	Lausanne	VD
Switzerland	Hôpital de Nyon	Nyon

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire Vaudois	European Society of Intensive Care Medicine

Countries where clinical trial is conducted

Estonia,  France,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of hypophosphatemia	Blood value < 0.8 mmol/l	1 day